Literature DB >> 21622860

Cytotoxic CD4+ T cell responses to EBV contrast with CD8 responses in breadth of lytic cycle antigen choice and in lytic cycle recognition.

Heather M Long1, Alison M Leese, Odette L Chagoury, Shawn R Connerty, Jared Quarcoopome, Laura L Quinn, Claire Shannon-Lowe, Alan B Rickinson.   

Abstract

EBV, a B lymphotropic herpesvirus, encodes two immediate early (IE)-, >30 early (E)-, and >30 late (L)-phase proteins during its replication (lytic) cycle. Despite this, lytic Ag-induced CD8 responses are strongly skewed toward IE and a few E proteins only, all expressed before HLA I presentation is blocked in lytically infected cells. For comparison, we examined CD4(+) T cell responses to eight IE, E, or L proteins, screening 14 virus-immune donors to overlapping peptide pools in IFN-γ ELISPOT assays, and established CD4(+) T cell clones against 12 defined epitopes for target-recognition assays. We found that the lytic Ag-specific CD4(+) T cell response differs radically from its CD8 counterpart in that it is widely distributed across IE, E, and L Ag targets, often with multiple reactivities detectable per donor and with IE, E, or L epitope responses being numerically dominant, and that all CD4(+) T cell clones, whether IE, E, or L epitope-specific, show strong recognition of EBV-transformed B cell lines, despite the lines containing only a small fraction of lytically infected cells. Efficient recognition occurs because lytic Ags are released into the culture and are acquired and processed by neighboring latently infected cells. These findings suggested that lytic Ag-specific CD4 responses are driven by a different route of Ag display than drives CD8 responses and that such CD4 effectors could be therapeutically useful against EBV-driven lymphoproliferative disease lesions, which contain similarly small fractions of EBV-transformed cells entering the lytic cycle.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21622860      PMCID: PMC3154640          DOI: 10.4049/jimmunol.1100590

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  49 in total

1.  Virus-specific cytotoxic CD4+ T cells for the treatment of EBV-related tumors.

Authors:  Anna Merlo; Riccardo Turrini; Sara Bobisse; Rita Zamarchi; Rita Alaggio; Riccardo Dolcetti; Josef Mautner; Paola Zanovello; Alberto Amadori; Antonio Rosato
Journal:  J Immunol       Date:  2010-04-12       Impact factor: 5.422

2.  Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses.

Authors:  A Leen; P Meij; I Redchenko; J Middeldorp; E Bloemena; A Rickinson; N Blake
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

3.  Inhibition of EBV-induced lymphoproliferation by CD4(+) T cells specific for an MHC class II promiscuous epitope.

Authors:  Ryusuke Omiya; Chantal Buteau; Hiroya Kobayashi; Carlos V Paya; Esteban Celis
Journal:  J Immunol       Date:  2002-08-15       Impact factor: 5.422

4.  Upregulation of interleukin 7 receptor alpha and programmed death 1 marks an epitope-specific CD8+ T-cell response that disappears following primary Epstein-Barr virus infection.

Authors:  Delphine Sauce; Martin Larsen; Rachel J M Abbott; Andrew D Hislop; Alison M Leese; Naeem Khan; Laura Papagno; Gordon J Freeman; Alan B Rickinson
Journal:  J Virol       Date:  2009-07-15       Impact factor: 5.103

5.  The lytic cycle of Epstein-Barr virus is associated with decreased expression of cell surface major histocompatibility complex class I and class II molecules.

Authors:  Sinéad Keating; Stuart Prince; Matthew Jones; Martin Rowe
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

6.  Patterns of Epstein-Barr virus latent and replicative gene expression in Epstein-Barr virus B cell lymphoproliferative disorders after organ transplantation.

Authors:  D Rea; C Fourcade; V Leblond; M Rowe; I Joab; L Edelman; M O Bitker; I Gandjbakhch; C Suberbielle; J P Farcet
Journal:  Transplantation       Date:  1994-08-15       Impact factor: 4.939

Review 7.  The immune response to Epstein-Barr virus.

Authors:  Margaret F C Callan
Journal:  Microbes Infect       Date:  2004-08       Impact factor: 2.700

8.  Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects.

Authors:  Andrew W Sylwester; Bridget L Mitchell; John B Edgar; Cara Taormina; Christian Pelte; Franziska Ruchti; Paul R Sleath; Kenneth H Grabstein; Nancy A Hosken; Florian Kern; Jay A Nelson; Louis J Picker
Journal:  J Exp Med       Date:  2005-09-05       Impact factor: 14.307

Review 9.  Cellular responses to viral infection in humans: lessons from Epstein-Barr virus.

Authors:  Andrew D Hislop; Graham S Taylor; Delphine Sauce; Alan B Rickinson
Journal:  Annu Rev Immunol       Date:  2007       Impact factor: 28.527

10.  Characterization of the CD4+ T cell response to Epstein-Barr virus during primary and persistent infection.

Authors:  Elisabeth Amyes; Chris Hatton; Damien Montamat-Sicotte; Nancy Gudgeon; Alan B Rickinson; Andrew J McMichael; Margaret F C Callan
Journal:  J Exp Med       Date:  2003-09-15       Impact factor: 14.307

View more
  37 in total

1.  Repression of CIITA by the Epstein-Barr virus transcription factor Zta is independent of its dimerization and DNA binding.

Authors:  Nicolae Balan; Kay Osborn; Alison J Sinclair
Journal:  J Gen Virol       Date:  2015-12-11       Impact factor: 3.891

2.  Signaling by the Epstein-Barr virus LMP1 protein induces potent cytotoxic CD4+ and CD8+ T cell responses.

Authors:  Il-Kyu Choi; Zhe Wang; Qiang Ke; Min Hong; Yu Qian; Xiujuan Zhao; Yuting Liu; Hye-Jung Kim; Jerome Ritz; Harvey Cantor; Klaus Rajewsky; Kai W Wucherpfennig; Baochun Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-08       Impact factor: 11.205

3.  Kaposi's sarcoma-associated herpesvirus inhibits expression and function of endothelial cell major histocompatibility complex class II via suppressor of cytokine signaling 3.

Authors:  L M Butler; H C Jeffery; R L Wheat; H M Long; P C Rae; G B Nash; D J Blackbourn
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

4.  Association of GATA2 Deficiency With Severe Primary Epstein-Barr Virus (EBV) Infection and EBV-associated Cancers.

Authors:  Jeffrey I Cohen; Lesia Dropulic; Amy P Hsu; Christa S Zerbe; Tammy Krogmann; Kennichi Dowdell; Ronald L Hornung; Jana Lovell; Nancy Hardy; Dennis Hickstein; Edward W Cowen; Katherine R Calvo; Stefania Pittaluga; Steven M Holland
Journal:  Clin Infect Dis       Date:  2016-05-11       Impact factor: 9.079

5.  Genomic diversity of Epstein-Barr virus genomes isolated from primary nasopharyngeal carcinoma biopsy samples.

Authors:  H Kwok; C W Wu; A L Palser; P Kellam; P C Sham; D L W Kwong; A K S Chiang
Journal:  J Virol       Date:  2014-07-02       Impact factor: 5.103

6.  Vaccination Produces CD4 T Cells with a Novel CD154-CD40-Dependent Cytolytic Mechanism.

Authors:  Rhea N Coler; Thomas Hudson; Sean Hughes; Po-Wei D Huang; Elyse A Beebe; Mark T Orr
Journal:  J Immunol       Date:  2015-08-21       Impact factor: 5.422

7.  Age-associated Epstein-Barr virus-specific T cell responses in seropositive healthy adults.

Authors:  D Cárdenas Sierra; G Vélez Colmenares; A Orfao de Matos; S Fiorentino Gómez; S M Quijano Gómez
Journal:  Clin Exp Immunol       Date:  2014-07       Impact factor: 4.330

8.  CD4 T cells specific for a latency-associated γ-herpesvirus epitope are polyfunctional and cytotoxic.

Authors:  Michael L Freeman; Claire E Burkum; Tres Cookenham; Alan D Roberts; Kathleen G Lanzer; Gail E Huston; Meghan K Jensen; John Sidney; Bjoern Peters; Jacob E Kohlmeier; David L Woodland; Linda F van Dyk; Alessandro Sette; Marcia A Blackman
Journal:  J Immunol       Date:  2014-11-05       Impact factor: 5.422

9.  T cell epitope screening of Epstein-Barr virus fusion protein gB.

Authors:  Haiwen Chen; Xiao Zhang; Shanshan Zhang; Xiaobing Duan; Tong Xiang; Xiang Zhou; Wanlin Zhang; Xinyu Zhang; Qisheng Feng; Yinfeng Kang; Jiangping Li; Lan Deng; Liang Wang; Xing Lv; Musheng Zeng; Yi-Xin Zeng; Miao Xu
Journal:  J Virol       Date:  2021-03-03       Impact factor: 5.103

10.  The Epstein-Barr Virus Major Tegument Protein BNRF1 Is a Common Target of Cytotoxic CD4+ T Cells.

Authors:  Josef Mautner; Uta Behrends; Dinesh Adhikary; Julia Damaschke
Journal:  J Virol       Date:  2020-07-16       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.